Waiv exists to catalyze precision medicine with clinical-grade, AI-powered tests that accelerate biomarker discovery and detection, outcome prediction, and treatment-response assessment across oncology.

Built on over seven years of validated medical-AI innovation and one of Europe’s largest multi-institutional data networks, Waiv delivers precise, accurate, and fast analyses that support treatment decisions. Waiv collaborates with global pharmaceutical companies, research institutions, diagnostic organizations and healthcare systems to bring scalable precision medicine to patients worldwide.

Waiv is backed by OTB Ventures and Alpha Intelligence Capital (AIC), with participation from Serena Data Ventures, Karista, and SistaFund, with an initial financing of $33 million dollars to expand its clinical testing solutions and fuel commercial expansion.